Thelansis Knowledge Partners "Metastatic Hormone Refractory Prostate Cancer" - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report – 2015 to 2030" report comprises of the Disease overview, classifications, stages or severity level, pathogenesis, identified and emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenarios, Patent landscape, reimbursement scenario; Public, Private, Medicare, Medicaid, Government, Private, Co-payment, Out of pocket, Epidemiology; Incidence, Prevalence, Mortality, and current therapy market share, Order of entry, patient share, Market uptake, Peak patient share, Disease burden, Annual cost of therapy, market forecast for USA, Germany, France, Italy, Spain, UK, Japan and China 2015 to 2030
Geographic Coverage
• United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
• China
Market estimation: 2015 – 2030
Report brief:
Epidemiology
This section provide the insights about historical and current patient pool (Incidence, Prevalence and mortality) and forecasted trend for 8 major markets (US, Germany, France, Italy, Spain, UK, Japan and China). The epidemiology research is one the key element of the report driven by meta-analysis, Systemic literature review and insights from KOL’s
Treatment Algorithm
The comprehensive details on country specific treatment and disease management for the patients in the US, Europe, Japan, and China. Future treatment paradigm and KOL’s perspective (HCP’s, Payers and Researcher) are the key strength of the report
Competitive Landscape
A thorough analysis of reported revenue, patient share and marketed trend for approved therapies however for pipeline assets we consider Phase I, Phase II and Phase III including their major milestones, study result, interim result, safety & efficacy data, key drivers, mechanism of action designation (Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review) geography level prioritization, asset level profile and probable launch date estimation
Market Outlook & Market Forecast
Historic, current and forecasted market trend (High, Base case, Low) of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better diagnosis of biomarkers. Key patient segment and market based on type, severity and stages of the disease. Disease burden, compliance rate, annual cost of therapy, reimbursement scenario, Patient share, Patient access
Market uptake and benchmarking
The market penetration for pipeline assets being derived on the basis of benchmarking the sales of launched assets specifically targeting the patient segment or overall indication or therapy area or country or region specific. Order of entry benchmark works as a critical element for defining the uptake curve for the pipeline assets. Many drug utilization study are being benchmarked to arrive at the current patient share for marketed therapies as well as off-label products. Market events are the major key factors which applied to the forecast model to optimize the year on year revenue estimation
Regulatory scenario
Country specific healthcare structure, regulatory bodies, HTA bodies, approval process for diagnostic and therapies, and work flow
Patent landscape
Country specific patent filings for approved therapies as well as pipeline assets, formulation patent, process patent (FDA, EMA, EPO, Orange book, JPO; Japan Patent Office) and fillings
Reimbursement Scenario
Country specific reimbursement Scenario; Public, Private, Medicare, Medicaid, Government, Private, Co-payment, Out of pocket
Key Report highlights
• 4 years of historical epidemiology data Epidemiology; Incidence, Prevalence, Mortality
• 11 years of epidemiology and market projections
• Incidence/ Prevalence patient population
• Mortality, survival and diagnosed patient pool
• Treated patient pool
• Treatment guidelines
• Competitive landscape (Marketed therapies, Off-label therapies, Pipeline assessment, Phase – I, II, III)
• Patient share
• Country specific revenue share and trend
• Market Opportunities assessment
• Key market and product event analysis
• Disease burden and annual cost of therapy
• Regulatory scenario
• Reimbursement Scenario
• Patent landscape
• HCP’s/ KOL’s perspective
• Payer’s perspective
• Analyst commentary Karyopharm Therapeutics Inc, Clovis Oncology, Inc., Glaxosmithkline, Nektar Therapeutics, Celldex Therapeutics, Asana Biosciences, Laekna Limited, Astrazeneca|Merck Sharp & Dohme Corp., Clovis Oncology, Inc., Astellas Pharma, Medivation, Inc., Constellation Pharmaceuticals, Bayer, Cellular Biomedicine Group Ltd., Zenith Epigenetics, Veru Inc., Kangpu Biopharmaceuticals, Ltd., Accelovance, Regeneron Pharmaceuticals, Trovagene, Inc., Essa Pharmaceuticals, Merck Sharp & Dohme Corp., Tracon Pharmaceuticals Inc., Pfizer, Medivation, Inc., Jiangsu Hengrui Medicine Co., Ltd., Astellas Pharma Inc, Janssen Pharmaceutical K.K., Beigene, Orion Corporation, Orion Pharma, Corcept Therapeutics, Medimmune Llc, Pellficure Pharmaceuticals, Inc, Taiho Oncology, Inc., Sichuan Haisco Pharmaceutical Group Co., Ltd., Fortis Therapeutics, Inc., Janssen Research & Development, Llc, Aptevo Therapeutics, Oncology Venture, Modra Pharmaceuticals, Bayer, Hinova Pharmaceuticals Usa, Inc., Progenics Pharmaceuticals, Inc., Bristol-Myers Squibb, Churchill Pharmaceutical Llc, Sanofi, Atridia Pty Ltd., Sotio A.S., Eli Lilly And Company, Advaxis, Inc., Arvinas Inc, Bayer, Endocyte, Bristol-Myers Squibb, Cellcentric Ltd., Pfizer, Astellas Pharma Inc, Astrazeneca, Prostate Cancer Uk, Pfizer, Dextech Medical Ab, Immunomedics, Inc., Suzhou Kintor Pharmaceutical Inc,, Tiziana Life Sciences, Plc, Hoffmann-La Roche, Bristol-Myers Squibb, Millennium Pharmaceuticals, Inc., Signalrx Pharmaceuticals, Inc., Beigene, Apollomics (Australia) Pty. Ltd., Apollomics Inc. (Formerly Cbt Pharmaceuticals, Inc.), Novotech (Australia) Pty Limited, Bristol-Myers Squibb, Aeon Therapeutics (Shanghai) Co., Ltd., Eureka Therapeutics Inc., Eli Lilly And Company, Astrazeneca, Aeon Therapeutics (Shanghai) Co., Ltd., Effector Therapeutics, Kyowa Kirin Pharmaceutical Development, Inc., Shanghai Haihe Pharmaceutical, Bayer, Exelixis, Merck Sharp & Dohme Corp., Shanghai Genechem Co., Ltd., Immunomedics, Inc., Clinica Universidad De Navarra, Sirtex Medical, Teclison Ltd., Nanobiotix